Uncategorized

There is a moment that happens to almost every executive who visits China for the first time. They walk into a store. Not a concept store. Not a flagship. A functioning grocery outlet. A mid-market lifestyle shop. A fast-fashion chain in a tier-two city.  And they go quiet. Not because it is impressive. Because it

NMPA China refers to the National Medical Products Administration, China’s national regulatory body for medical devices and the authority responsible for drug registration. For any company seeking market access in China’s healthcare sector, NMPA China approval is the single most important regulatory milestone.  In 2025, the agency approved 14,187 medical devices and IVDs, an 8.0%

CAS Space is a Chinese commercial rocket developer and launch provider with roots in the Institute of Mechanics at the Chinese Academy of Sciences. Its Kinetica-1, also called Lijian-1, serves satellite missions, while Kinetica-2 expands its offering into larger liquid launch vehicles and cargo transportation. The larger rocket completed its maiden flight on March 30,

China’s biotech sector is becoming a major source of new medicines, research partnerships, and drug development capacity. Its commercial relevance stems from a mix of domestic innovation, international licensing, and an expanding clinical research system. China recorded approximately $110 billion in announced overseas drug deals during the first half of 2026, according to regulatory data

CASC China refers to China Aerospace Science and Technology Corporation (CASC), the state-owned group that develops and manufactures rockets, satellites, and spacecraft for China’s space program. Its activities connect national missions with the industrial capacity behind commercial space services. CASC offers a concrete way to examine China’s development as a technology hub. Its recent work

Chinese biotech companies have shifted from fast followers to global licensing partners. In 2025, Chinese firms signed 127 out-licensing deals with total transaction value reaching $144 billion, while upfront payments reached $8 billion. Commercialization is scaling alongside licensing, with several Chinese drugmakers now generating multibillion-yuan revenue from innovative medicines. The companies driving this shift combine

China Aerospace Science and Industry Corporation (CASIC) has moved from missile maker to commercial space power. In 2025, China’s commercial space sector conducted 50 launch missions, with 311 commercial satellites placed into orbit. CASIC, through subsidiaries like ExPace and CAS Space, sits at the center of this shift.  The company’s Kuaizhou rockets now perform regular

A short connection between a metro station and a hospital gives an autonomous shuttle a clear task. Operators know where passengers board, where they need to go, and which road conditions the vehicle must handle. China’s fixed-route deployments offer a practical way to examine how autonomous public transport develops. Defined corridors support repeatable testing, scheduled

The China medical devices sector combines substantial manufacturing capacity with an expanding pipeline of advanced clinical products. China had 33,210 medical-device manufacturers at the end of 2025, according to National Medical Products Administration (NMPA) statistics. Its commercial relevance spans equipment sourcing, technology partnerships, and access to Chinese healthcare customers. The commercial question is where that

A traffic camera can spot a growing queue. The harder task is getting the next intersection, the approaching bus, and the control room to respond together. An Intelligent Transportation System connects sensors, communications, and software so transport operators can act on changing road conditions. Traffic management is one application; passenger information, fleet coordination, and road